RenovoRx (RNXT)
NASDAQ:RNXT
Want to see RNXT full AI Analyst Report?
RNXT Stock Chart & Stats
$1.00
-$0.05(-3.65%)
At close: 4:00 PM EST
$1.00
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.45
Previous CloseN/A
Volume39.72K
Average Volume (3M)288.82K
Market Cap
$41.45M
Enterprise Value$20.98M
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$186.00K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 13, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue14.09
Enterprise Value/Gross Profit17.90
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$7.00Price Target Upside600.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$3.20M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsSustained high gross margins (~79% TTM; 85.1% in Q1 2026) indicate attractive per-procedure economics for the RenovoCath device. Durable unit economics can support profitable scaling as procedures increase, improving leverage of revenue over fixed SG&A and R&D costs.
Rapid Commercial Expansion & Physician AdoptionA growing installed base (16 active centers, 48 total pipeline) and reported repeat orders imply durable adoption and network effects from physician advocacy. Expanding site conversions create a structural revenue runway beyond one-off sales and support scaling of per-procedure volumes.
Strengthened Liquidity & Low LeverageAn oversubscribed $10M financing plus ~$12.4M cash provides meaningful runway into H2 2027 and reduces immediate refinancing pressure. Combined with very low reported debt, this strengthens near-term financial flexibility to fund commercialization and the pivotal trial completion.
Bears Say
Persistent Negative Operating Cash FlowConsistent, large negative operating and free cash flows (~-$11.3M TTM) reflect that operating costs materially exceed revenues. This persistent burn forces ongoing reliance on financing, constrains reinvestment optionality, and elevates dilution or refinancing risk if commercial ramp slows.
Low Absolute Revenue & Dependence On ConversionsStrong growth rates stem from a small base: absolute revenues remain modest (Q1 $563K; TTM $1.49M). Achieving guided revenue requires predictable conversion of trial and pipeline sites; failure or delays in conversions would impair cash generation and slow path to scale.
Pivotal Trial Timing And Execution RiskThe Phase III TIGeR‑PaC program remains incomplete and is a gating item for broader adoption and reimbursement gains. Trial outcomes and timing (data mid‑to‑late 2027) create structural execution risk that will materially affect commercial conversions and long-term revenue trajectory.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.45 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $41.45M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Aug 13, 2026 which is in 53 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on May 14, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.01.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.07.
How many shares outstanding does RenovoRx have?
RenovoRx has 45,052,708 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -4.094%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (600.00% Upside)
$7.00 (600.00% Upside)
Insider Transactions
Bought Shares
Worth $19.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
-138.61%
Trailing 12-Months
Asset Growth
-12.80%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RNXT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful operational milestones: record quarterly revenue with very high gross margins, rapid expansion of active centers and a sizable prospect pipeline, near-completion of the pivotal Phase III trial, and a successful $10M private placement providing runway into H2 2027. Offsetting factors include still-modest absolute revenue, sizable operating expenses (R&D $1.2M; SG&A ~$2.7M), remaining trial and event targets to achieve, and timing/convertibility risk of pipeline centers. Overall the positive execution on commercial scaling, healthy margins, and a reinforced balance sheet materially outweigh the near-term risks described.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$7.00
▲(600.00% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.34% Insiders
3.91% Mutual Funds
12.96% Other Institutional Investors
76.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---